A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease

Overview of attention for article published in BMC Nephrology, October 2022

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (67th percentile)
Good Attention Score compared to outputs of the same age and source (67th percentile)

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 5,728 followers.

RT @nephronus: In #ADPKD #tolvaptan versus no Rx. Rx group spent more time in earlier CKD stages and had later onset of ESRD. Findings high…

RT @nephronus: In #ADPKD #tolvaptan versus no Rx. Rx group spent more time in earlier CKD stages and had later onset of ESRD. Findings high…

RT @nephronus: In #ADPKD #tolvaptan versus no Rx. Rx group spent more time in earlier CKD stages and had later onset of ESRD. Findings high…

RT @nephronus: In #ADPKD #tolvaptan versus no Rx. Rx group spent more time in earlier CKD stages and had later onset of ESRD. Findings high…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 1 additional X posts.